Genzyme Surgical Is Out Of General's Shadow Following January Run-up
This article was originally published in The Gray Sheet
Executive Summary
Wall Street began to take note in January of Genzyme Surgical Products' leading position in the minimally invasive cardiac surgery market, as the stock price of the Genzyme General spin-off jumped 74.2%. The issue closed the month at 10-1/8, up 5-3/16.
You may also be interested in...
Genzyme Biosurgery To Include Tissue Repair/Surgical Units, Biomatrix
Genzyme Tissue Repair's 26-person Carticel sales force could aid Biomatrix' marketing efforts for Synvisc following the merger of Genzyme Surgical Products, Genzyme Tissue Repair and Biomatrix to create a new company, Genzyme Biosurgery.
Genzyme Biosurgery To Include Tissue Repair/Surgical Units, Biomatrix
Genzyme Tissue Repair's 26-person Carticel sales force could aid Biomatrix' marketing efforts for Synvisc following the merger of Genzyme Surgical Products, Genzyme Tissue Repair and Biomatrix to create a new company, Genzyme Biosurgery.
Summit's Integrated Wavefront Technology To Break In 2001
Summit Technology, backed by encouraging results from 20 patients treated thus far in an ongoing feasibility trial, is hoping to market a customized refractive laser surgical system integrating the company's CustomCornea wavefront measuring device with its LADARVision system by the end of 2001.